Quinuclidine α7 Receptor Ligands for Cognitive Deficits
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for schizophrenia and neurodegenerative disorders, such as Alzheimer's disease, are limited in effectively addressing negative symptoms and cognitive deficits, and often come with significant side effects, while existing therapies for these conditions do not adequately target the underlying pathophysiology of these disorders.
Innovation Solution
Development of compounds that act as selective ligands for the nicotinic α7 receptor, which are agonists or partial agonists, to improve cognitive function and potentially modify disease progression by interacting with the α7 nicotinic receptor, thereby influencing neurotransmitter release and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antipsychotic agents targeting the dopaminergic system are used, then positive symptoms are reduced, but negative symptoms and cognitive deficits are not relieved and side effects occur
Solution Approach 1:
The patent develops compounds that act as agonists or partial agonists at multiple nicotinic acetylcholine receptor subtypes (particularly α4β2 and α7), enabling a single agent to address positive symptoms, negative symptoms, and cognitive deficits simultaneously. This multi-receptor targeting approach provides broader therapeutic coverage compared to traditional D2-only antipsychotics.
Solution Approach 2:
The invention employs structure-activity relationship optimization to modify the chemical structure of quinuclidine compounds, adjusting parameters such as substituent groups (R1, R2, R3) to enhance affinity and selectivity for specific nicotinic receptor subtypes. This allows fine-tuning of pharmacological properties to achieve desired therapeutic effects while minimizing side effects.
2Reliability
If current antipsychotic agents are used, then positive symptoms are reduced, but unwanted and limiting side effects occur
Solution Approach 1:
The patent introduces nicotinic acetylcholine receptors as intermediary targets that mediate the therapeutic effects of the compounds. By acting through this intermediary pathway rather than directly blocking D2 receptors, the compounds achieve antipsychotic effects while avoiding many of the side effects associated with direct dopaminergic antagonism, such as extrapyramidal symptoms and tardive dyskinesia.
3Reliability
If selective ligands for nicotinic α7 receptor are developed, then cognitive function is improved and disease progression is modified, but selectivity and affinity optimization is required
Solution Approach 1:
The patent applies local quality optimization by introducing specific substituent groups at defined positions (R1, R2, R3) on the quinuclidine core structure to enhance binding affinity and selectivity for the α7 receptor subtype. Each substituent is carefully chosen to interact with specific residues in the α7 binding pocket, thereby improving local interactions and overall selectivity.
Data Source
AI summary
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.